If you experience your Apple Watch not tracking exercise, try resetting your sync data in the Watch app. You can also re-calibrate your Apple Watch by going for a walk or a run and recording the ...

Many pilots will recognise my situation. About 230 hours in my logbook plus a bit of time learning to glide, but I had started learning in 1977, 38 years before. Then I bought an old ? but lovely ?

Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...

Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

Scientists used tiny new sensors to follow the insects on journeys that take thousands of miles to their winter colonies in Mexico. Scientists used tiny new sensors to follow the insects on journeys ...

Vor Biopharma shares fell sharply Tuesday in premarket trading after the company priced its $100 million offering below recent trading prices. Shares traded 31% lower ahead of the morning bell at ...

Grand Slam Track (GST), the league founded by four-time Olympic champion Michael Johnson, has been provided funding by its investors to cover half of what it owes to its athletes, sources with ...

This 1 Travel Mistake Got My Phone Stolen Abroad—and Here’s How I Avoid It Now for Future Trips Birkenstock Clogs and Sandals Are Up to 40% Off in This Rare Spring Sale—Shop the Best Deals From $33 ...

Vor Biopharma (NASDAQ:VOR) has been upgraded to Buy from Hold at Stifel as confidence in the company’s long-term potential has grown following prospects for its lead asset, telitacicept. The shares of ...

Dr. Khan brings decades of global medical affairs, commercial, and scientific leadership across multiple therapeutic areas including seven successful product launches CAMBRIDGE, Mass., Sept. 23, 2025 ...

China biotech RemeGen and its new U.S. partner Vor Bio are on a roll with their first-in-class autoimmune treatment telitacicept. Two weeks after RemeGen revealed the success of a China phase 3 trial ...